Physician profile
Mandy Robertson
NPI 1790730174
$3,767.32
in general payments reported to CMS, 2019-2025
40 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $141 · 2021: $44.42 · 2022: $53.56 · 2024: $2,478 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,850 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.67 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $548.76 | 2019-2025 | Enhertu, Lynparza, Tagrisso |
| Pfizer INC. | $305.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $290.05 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $244.61 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $225.66 | 2019-2024 | Keytruda, Reblozyl, Welireg |
| Abbvie INC. | $203.20 | 2024-2025 | |
| Seagen INC. | $190.54 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $135.90 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Genmab U.S., INC. | $133.81 | 2024 | Epkinly |
| Janssen Biotech, INC. | $117.39 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Celgene Corporation | $110.58 | 2024-2025 | Reblozyl, Onureg |
| Novocure INC. | $100.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Eisai INC. | $83.37 | 2019-2024 | |
| Stemline Therapeutics INC. | $79.33 | 2024-2025 | Orserdu |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.